Skip to main content

Table 3 Change in disease characteristics (delta median values) in ACPA reactivity-positive versus reactivity-negative patients

From: The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

  Delta DAS 6 months Delta DAS 12 months Delta DAS 24 months Delta US GS 12 months Delta US GS 24 months Delta US PD 12 months Delta US PD 24 months Delta vdHSS T 12 months Delta vdHSS T 24 months
   p   p   p   p   p   p   p   p   p
Fibβ 60–74 + −1.9 0.04 −2.0 < 0.01 − 2. 0 0.02 − 12 < 0.01 − 13 < 0.01 −6 < 0.01 − 6 < 0.01 0.5 0.92 1.0 0.69
– − 2.5 −2.6 −2.6 − 19 −21 −9 −10 0.5 1.0
Vim 60–75 + −1.9 < 0.01 − 1.9 < 0.01 − 2.0 0.02 − 12 < 0.01 − 13 < 0.01 − 6 0.06 − 6 0.02 0.5 0.59 1.0 0.68
– −2.6 − 2.6 − 2.6 −17 − 17 −8 −8 0.5 1.0
H4 31–50 + −1.9 < 0.01 − 1.9 < 0.01 −2.0 < 0.01 − 12 0.05 − 13 < 0.01 − 6 0.08 − 6 0.02 0.5 0.15 1.0 0.81
– −2.5 − 2.8 − 2.7 − 15 −17 −7 −8 0.5 1.0
CEP-1 + −2.0 0.75 − 2.1 0.79 −2.1 0.48 −12 0.23 − 14 0.24 −6 0.17 −6 0.14 0.5 0.50 1.0 0.41
– −2.1 −2.2 −2.0 −14 −14 −7 − 7 0.5 1.0
Fil 307–324 + −1.9 0.01 −1.8 < 0.01 − 1.9 0.01 − 12 0.06 − 13 0.01 −6 0.03 −5 0.01 0.5 0.75 1.0 0.76
– −2.4 −2.5 −2.5 −16 −16 −7 − 7 0.5 1.0
Fibα 573 + −1.9 < 0.01 −1.8 < 0.01 − 1.9 < 0.01 − 13 0.36 − 14 0.12 −6 0.21 −6 0.08 0.5 0.89 1.0 0.77
– −2.5 −2.6 −2.4 −13 −15 −7 −7 0.5 1.5
Fibβ 36–52 + −1.9 0.02 −1.9 < 0.01 − 1.9 < 0.01 −12 0.23 −14 0.09 −6 0.08 −5 0.02 0.5 0.89 1.0 0.58
– −2.4 −2.5 −2.5 −14 − 14 −7 −7 0.5 1.5
H3 1–30 + −2.1 0.97 − 2.2 0.97 − 2.0 0.44 −12 0.31 − 13 0.04 −6 0.25 −6 0.09 0.5 0.24 1.0 0.45
– −2.0 −2.1 −2.2 −14 −16 −7 −7 0.5 1.2
H4 14–34 + −1.9 0.07 −2.0 0.12 −2.0 0.14 −12 0.46 −12 0.02 −7 0.63 −6 0.54 0.5 0.32 1.5 0.10
– −2.1 −2.3 −2.2 −14 −16 −6 −6 0.5 1.0
H3 21–44 + −2.0 0.48 −2.0 0.31 −2.0 0.37 −12 0.29 −13 0.39 −6 0.28 −6 0.38 0.5 0.39 1.5 0.76
– −2.0 −2.2 −2.2 −15 −15 −7 −7 0.5 1.0
Fibα 621–635 + −1.7 0.04 −1.8 0.04 −1.9 0.03 −11 0.02 −13 0.01 −6 0.09 −6 0.05 0.5 0.20 1.0 0.22
– −2.3 −2.4 −2.2 −15 −16 −7 −7 0.5 1.5
Vim 2–17 + −1.9 0.04 −1.8 0.02 −1.8 0.01 −12 0.12 −12 < 0.01 −6 0.21 −5 0.04 0.5 0.90 1.0 0.87
– −2.2 −2.3 −2.3 −14 −16 −7 −7 0.5 1.0
Fibα 36–50 + −2.0 0.83 − 2.0 0.74 − 2.0 0.45 −11 0.09 − 12 0.10 −5 0.02 −5 0.02 0.5 0.61 1.0 0.52
– −2.0 −2.2 −2.2 −14 −15 −7 −7 0.5 1.0
Fibα 591 + −1.9 0.08 − 1.8 0.03 − 1.8 0.01 − 13 0.69 − 16 0.70 −6 0.84 −6 0.77 0.5 0.41 1.0 0.58
– −2.2 −2.3 −2.3 −13 −14 −6 −7 0.5 1.5
Fibβ 74 + −1.8 0.41 −2.0 0.79 −2.1 0.55 −12 0.36 −13 0.94 −7 0.82 −7 0.98 0.5 0.06 1.5 0.54
– −2.1 −2.2. −2.0 −13 −14 −6 −6 0.5 1.0
Fibβ 72 + −2.0 0.84 −2.0 0.73 −1.9 0.78 − 16 0.19 − 17 0.21 −7 0.13 −9 0.11 0.2 0.98 0.5 0.51
– −2.0 −2.2. −2.1 −12 −14 −6 −6 0.5 1.0
  1. Anti-citrullinated protein antibody (ACPA) reactivities are sorted by decreasing frequency in the cohort: p values (p) were derived from the Mann-Whitney U test; statistically significant differences are in italics
  2. Abbreviations: DAS Disease Activity Score (0–10), SJC swollen joint count (0–44), US ultrasound, GS grey scale (0–96), PD power Doppler 0–96), vdHSS van der Heijde modified Sharp score, T total (0–448), Fib fibrinogen, Vim vimentin, H histone, CEP-1 citrullinated enolase peptide-1, Fil filaggrin; numbers referring to amino acid sequence
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us